Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers
An investigational PET imaging agent — zirconium-89 (89Zr)-deferoxamine (DFO)-girentuximab — identified clear cell renal cell carcinoma (ccRCC) with high sensitivity and specificity, according to results from the phase III ZIRCON trial. Use of the agent achieved sensitivity and specificity rates of 85.5% (95% CI 79.8-89.8) and 87% (95% CI 78.8-92.3), respectively, reported Peter Mulders, MD, […]